Low-Dose Naltrexone (LDN) for Immune Modulation: Autoimmune, Inflammation, and Safety Evidence

Low-dose naltrexone (LDN) is naltrexone used off-label at low doses to influence immune and pain signaling. It is studied for autoimmune, inflammatory, and post-viral symptoms through opioid-receptor, endorphin, and microglial pathways, but evidence varies by condition and it needs clinician screening 1, 2, 3.

What is low-dose naltrexone?

Low-dose naltrexone (LDN) is a lower-dose use of naltrexone, an opioid antagonist drug class medication. Standard oral naltrexone is FDA-approved at 50 mg for opioid use disorder and alcohol use disorder, while LDN is an off-label approach discussed in immune, pain, and inflammatory care 1, 2.

Naltrexone blocks opioid receptors, including the mu-opioid receptor. In LDN research, the goal is not long opioid blockade; the theory is that a short block may shift the body’s own opioid-like signals, including endorphins and enkephalins 2, 3.

How LDN differs from standard-dose naltrexone

The FDA-approved naltrexone tablet is 50 mg, and its label warns about opioid withdrawal, liver injury risk, and the need to be opioid-free before starting therapy 1. In contrast, LDN studies often describe lower strengths, such as 4.5 mg in fibromyalgia, Crohn’s disease, and multiple sclerosis trials, but those trials do not make LDN FDA-approved for those conditions 4, 7, 8.

Why LDN is usually compounded

FDA-approved naltrexone tablets are not manufactured in the low strengths commonly used in LDN research. For that reason, LDN is often prepared by a state-licensed 503A compounding pharmacy for a specific patient after a licensed provider decides it is appropriate.

At Chia, we offer Low-Dose Naltrexone tablets through a fully online evaluation. Plans currently start at $79/mo, and medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door.

How does LDN modulate the immune system?

LDN’s immune effect is thought to come from two linked systems: opioid-receptor signaling and nervous-system immune cells called microglia. The proposed pathways are biologically plausible, but human outcomes are still condition-specific and often based on small studies 2, 3.

Transient opioid-receptor blockade

LDN briefly blocks opioid receptors. Reviews propose that this short blockade may lead to a rebound in endogenous opioids, such as endorphins and enkephalins, which help regulate pain, immune activity, and stress responses 2, 3.

This differs from standard-dose naltrexone, which is used for longer receptor blockade in opioid or alcohol use disorder 1. LDN is being studied for a different timing pattern, not as a substitute for addiction-treatment dosing.

Microglia, TLR4, and neuroinflammation

Microglia are immune-like cells in the brain and spinal cord. Younger and colleagues described LDN as a possible glial-cell modulator and discussed toll-like receptor 4, or TLR4, as one proposed pathway for lowering inflammatory signaling 3.

That mechanism matters because many autoimmune, chronic pain, and post-infectious conditions include pain amplification, fatigue, brain fog, or inflammation-related symptoms. The trade-off is that LDN can still cause vivid dreams, insomnia, nausea, headache, or mood changes, and it is not safe with opioid medications 1, 2, 4.

Which autoimmune or inflammatory conditions have evidence for LDN?

LDN evidence is uneven across conditions. Fibromyalgia, Crohn’s disease, and multiple sclerosis have small human trials, while Hashimoto’s thyroiditis, Long COVID, ME/CFS, and chronic pain syndromes have earlier or mixed data; individual results vary, and safety screening still matters.

Fibromyalgia

Fibromyalgia is not classically autoimmune, but it is often grouped with immune and inflammatory pain conditions because central sensitization and neuroinflammation may play a role. In a randomized, double-blind, placebo-controlled crossover trial, Younger et al. studied 4.5 mg low-dose naltrexone nightly in 31 women with fibromyalgia and found greater pain reduction than placebo; side effects included vivid dreams and headache, and the study was small 4.

A smaller pilot study by Younger and Mackey also studied 4.5 mg naltrexone in fibromyalgia and reported symptom improvement in some participants 5. These studies make fibromyalgia one of the better-studied LDN use cases, but they are not large enough to predict who will respond.

Crohn’s disease and IBD

Crohn’s disease is an inflammatory bowel disease with immune dysregulation. In an open-label pilot study, Smith et al. administered 4.5 mg naltrexone daily to adults with active Crohn’s disease and reported clinical response in many participants, with sleep disturbance as one noted side effect 6.

In a later randomized placebo-controlled trial, Smith et al. again studied 4.5 mg naltrexone in adults with active Crohn’s disease and reported improved clinical activity scores and endoscopic response compared with placebo 7. This is encouraging, but LDN should not replace prescribed IBD medications, lab monitoring, colonoscopy surveillance, or gastroenterology care.

Multiple sclerosis

Multiple sclerosis, or MS, is an autoimmune disease of the central nervous system. Cree et al. studied 4.5 mg low-dose naltrexone nightly in an 8-week crossover trial in people with MS and reported quality-of-life improvements in some mental-health measures, while the study was not designed to prove fewer relapses or slower disease progression 8.

Gironi et al. studied LDN in primary progressive MS and reported that it was generally well tolerated, but evidence for disability change was limited 9. For MS, LDN is best viewed as a symptom-focused adjunct being studied, not a substitute for disease-modifying therapy or neurology care.

Hashimoto’s thyroiditis and autoimmune thyroid disease

Hashimoto’s thyroiditis is an autoimmune thyroid condition. Interest in LDN comes from its proposed immune-modulating effects, but direct evidence is weak: a Norwegian prescription-database study did not find evidence that starting LDN reduced thyroid-hormone use in people with hypothyroidism 10.

That means LDN should not be expected to normalize thyroid antibodies, replace levothyroxine, or correct thyroid hormone levels. A clinician should monitor thyroid labs, symptoms, and medication changes because under-treated hypothyroidism can affect energy, mood, cholesterol, menstrual cycles, and weight.

Long COVID and post-viral syndromes

Long COVID, also called post-acute sequelae of SARS-CoV-2 infection, can include fatigue, pain, sleep problems, brain fog, and post-exertional symptom flares. Bonilla et al. reported a clinical cohort using LDN for Long COVID symptoms and found symptom-improvement signals, but the study was observational and cannot prove cause and effect 12.

Because Long COVID can overlap with dysautonomia, mast-cell symptoms, thyroid disease, anemia, sleep disorders, and mood symptoms, LDN should be considered only after a clinician reviews the full picture. Side effects like insomnia or vivid dreams can be especially important when poor sleep is already a major symptom.

Chronic pain with neuroinflammation

Complex regional pain syndrome, or CRPS, is a severe chronic pain condition with inflammatory and nervous-system features. Chopra and Cooper published case reports describing LDN use in CRPS and discussed glial-cell modulation; case reports can identify signals, but they cannot prove average benefit or safety for a broad group 11.

CRPS care often requires pain specialists, physical therapy, mental-health support, and careful medication planning. LDN’s main safety issue still applies here: it can block opioid pain medicines and may trigger withdrawal in opioid-dependent patients 1.

ME/CFS and post-viral fatigue

Myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS, is a complex illness that can follow infections and often includes post-exertional malaise. Published case reports describe LDN use in ME/CFS, but case reports are early evidence and do not establish a standard treatment effect 13.

For post-viral fatigue, the practical goal is careful evaluation, not a single-medication answer. A clinician should screen for anemia, thyroid disease, sleep apnea, medication effects, depression, dysautonomia, and inflammatory disease while weighing LDN’s possible benefits against sleep, headache, GI, liver, and opioid-related risks 1, 13.

How do providers approach LDN dosing and titration?

LDN dosing is individualized because this use is off-label and patients vary in sleep sensitivity, opioid exposure, liver history, and symptom goals. In the medical literature, LDN is commonly described around 1–5 mg daily, and several trials used 4.5 mg, but those are study-attributed doses rather than instructions for a reader 2, 4, 7.

In clinical practice, a provider may use a lower starting strength and adjust over time if tolerated. That provider-guided approach is one reason compounding matters: it allows patient-specific strengths that are not available as standard commercial naltrexone tablets.

Patients may notice sleep changes quickly, while immune, pain, or fatigue-related goals are usually assessed over weeks to months in studies and clinical follow-up. If side effects occur, a clinician may review timing, strength, other medications, and whether LDN still fits the patient’s goals.

What are the side effects, and who should not take LDN?

Naltrexone safety matters even at low doses. The most important contraindication is current opioid use or opioid dependence because naltrexone can block opioid pain medicines and can precipitate withdrawal 1.

• Current opioid use, opioid dependence, or expected need for opioid pain medicine requires clinician review and may make naltrexone unsafe 1.
• Acute hepatitis, significant liver disease, or abnormal liver tests require careful screening because naltrexone has liver-related warnings 1.
• Pregnancy and breastfeeding require an individualized risk-benefit review; LDN should not be started without a licensed clinician’s guidance.
• Common LDN side effects discussed in studies and reviews include vivid dreams, insomnia or sleep disruption, headache, nausea, diarrhea, and abdominal discomfort 2, 4, 6.
• Mood changes, dizziness, or worsening fatigue should be reported promptly, especially in people with complex chronic illness.

Many side effects described in LDN studies are mild, but “mild” does not mean unimportant. For a person with autoimmune flares, poor sleep, chronic pain, or Long COVID, even vivid dreams or insomnia can change quality of life.

How can you access LDN through Chia?

Chia offers LDN tablets for eligible patients after a fully online medical evaluation. You complete a short health questionnaire, then a licensed US provider reviews your history, medications, symptoms, and safety factors before deciding whether LDN is clinically appropriate.

If prescribed, LDN is compounded by a state-licensed US 503A pharmacy and shipped to your door. Dosing is provider-guided and adjusted over time, and patients can message the care team through the patient portal between visits.

LDN is not primarily an evidence-based weight-loss medication. If weight, insulin resistance, or appetite is a major concern, our providers may discuss metabolic options such as compounded semaglutide, compounded tirzepatide, the Weight + Energy protocol, or the Weight + Muscle protocol, when clinically appropriate.

How is LDN different from GLP-1 medications?

LDN and GLP-1s are used for different primary goals. LDN is mainly discussed for immune, inflammatory, and pain signaling, while semaglutide and tirzepatide are incretin-based medications studied for weight and metabolic outcomes 2, 14, 15.

Compounded semaglutide and compounded tirzepatide are not FDA-approved and do not have FDA-evaluated outcomes data. Their role is different from LDN, and a provider should match treatment to the patient’s diagnosis, goals, risks, and medications.

Who should discuss LDN with a licensed clinician?

LDN may be worth discussing if you have a diagnosed autoimmune, inflammatory, post-viral, or chronic pain condition and your current care plan is not fully meeting your goals. The discussion should include your diagnosis, labs, medications, opioid exposure, liver history, pregnancy status, and what symptom would be tracked over time 1, 2.

The safest next step is not guessing at a dose. It is a medical review that checks whether LDN fits the broader plan, whether standard care is already optimized, and whether the possible upside is worth the side-effect and interaction risks.

Frequently asked questions

Keep reading

Peptides

LL-37 Peptide: What It Is, How It Works, and What the Research Shows

Longevity Peptides

KPV Peptide: Uses, Evidence, and Safety Explained

Longevity

Copper Peptides (GHK-Cu): What They Do, Benefits, Side Effects, and How to Use Them